Latest Antigen Express Inc. Stories
WORCESTER, Mass. and TORONTO, Aug. 18, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) announced today that the Company's wholly-owned subsidiary Antigen Express, Inc. (www.antigenexpress.com) presented an update of the ongoing Phase 2 trial with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in patients with breast cancer at Cambridge Healthtech Institute's Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit held August 16-18,...
WORCESTER, Mass. and TORONTO, Aug. 2, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) is pleased to provide its shareholders with a corporate update of developments that have been achieved since the appointment of Mark Fletcher as President & Chief Executive Officer on September 29, 2010. "Since my appointment as President & Chief Executive Officer of Generex, I have made it a priority to proactively communicate significant catalysts to the...
WORCESTER, Mass. and TORONTO, July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology. Antigen Express, Inc., the Company's wholly-owned subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. AE37, an Ii-Key HER-2 hybrid, is currently the subject of a...
WORCESTER, Mass., July 11, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (the "Company") (www.generex.com) (OTCBB: GNBT) today announced that it entered into a securities purchase agreement with certain institutional investors on July 8, 2011. The investors have agreed to purchase at the initial closing an aggregate of 2,575 shares of the Company's newly designated non-voting Series A 9% Convertible Preferred Stock ("convertible preferred stock") and warrants to purchase up to an...
WORCESTER, Mass. and TORONTO, June 15, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that Jos van der Woert has been appointed to act as Chief Executive Officer of its wholly-owned subsidiary, Antigen Express, Inc., following its spinout. From 2003 to 2010, Mr. van der Woert was an executive with Schering-Plough Corporation, concluding his tenure there as General Manager and Group Vice-President, Global Oncology and Virology. From...
WORCESTER, Mass. and TORONTO, May 3, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced publication of results of studies applicable to the early diagnosis, and possibly treatment of, Type 1 diabetes. The study, entitled: "Recognition of Ii-Key/MHC Class II Epitope Hybrids Derived from Proinsulin and GAD Peptides by T Cells in Type 1 Diabetes" appears in the April issue of the international peer-reviewed journal Hormone and Metabolism...
WORCESTER, Mass., and TORONTO, April 5, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced it has launched its redesigned corporate website consistent with new management's drive to establish a focused and transparent approach to the development and approval of the Company's pipeline of diabetes and immunotherapeutic vaccine products. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) Aside from a new look, the Company's...
WORCESTER, Mass. and TORONTO, April 4, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced today the publication of a report comparing the clinical characteristics of three different immunotherapeutic peptide vaccines designed for immunotherapy of breast cancer. One of those, AE37, is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). (Logo:...
WORCESTER, Mass. and TORONTO, March 30, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) held a press conference earlier today at the NASDAQ Marketsite in New York City to unveil management's strategic development plan for the Company's future growth. A video of the press conference will be made available on the Generex website. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b ) The Generex Management Team John Barratt, the...
WORCESTER, Mass., March 24, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTC Bulletin Board: GNBT) today provided further information regarding the Company's press conference and investor call scheduled for March 30, 2011 to discuss management's strategic development plan for the Company's future growth. (Logo: https://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b) The details of the press conference are as follows: Date: March 30,...
